Beyond Barriers Therapeutics
3 known investors
Beyond Barriers Therapeutics develops BBT-101, an intranasal therapy for mild and moderate concussions intended for rapid deployment at the point of injury. The company focuses on providing the first FDA-approved frontline treatment for brain injuries across military, athletic, and civilian populations.
BiotechDigital HealthMedical Devices